SynEVOL, Global, Memphis, TN (2026)

11/05/2026

AI-Identified Natural Peptide Suppresses Appetite and Promotes Fat Loss Without Side Effects

Courtesy of SynEvol

SynEVOL researchers highlight a recent Nature publication from Stanford Medicine that uncovers a naturally occurring, 12-amino-acid peptide capable of curbing appetite and driving fat-specific weight loss in animal models. Led by assistant professor of pathology Katrin Svensson and postdoctoral scholar Laetitia Coassolo, the research team deployed a custom machine-learning platform called Peptide Predictor to scan more than 2,600 uncharacterized human prohormone cleavage fragments. By screening the top 100 candidates in laboratory-grown neuronal cultures, the investigators identified a previously unrecognized signaling molecule—named BRP after its parent protein, BRINP2—that boosted neuronal activation tenfold compared with untreated controls.

The findings reveal that administering BRP via intramuscular injection before feeding reduced voluntary food intake by up to 50% within one hour in both lean mice and minipigs, whose metabolic and eating patterns closely mirror human physiology. Over a 14-day treatment regimen in diet-induced obese mice, daily BRP administration produced substantial weight loss driven almost entirely by reductions in adipose tissue rather than lean muscle mass. Treated animals also demonstrated markedly improved glucose and insulin tolerance without exhibiting nausea, constipation, food aversion, or altered water intake.

Beyond metabolic efficacy, the study mapped how BRP engages central appetite-regulating circuits through a mechanism completely distinct from existing glucagon-like peptide-1 (GLP-1) medications. While drugs such as semaglutide act broadly across receptors in the gut, pancreas, brain, and peripheral organs, neural activity tracing showed that BRP acts selectively within the hypothalamus—the brain's primary command center for hunger and energy balance. Mechanistic experiments confirmed that BRP induces central FOS activation independently of GLP-1, leptin, and melanocortin-4 receptors, establishing a separate non-incretin neuroendocrine pathway.

Why does this matter? While GLP-1 receptor agonists have transformed obesity care, their systemic receptor footprint frequently triggers gastrointestinal distress and contributes to unwanted loss of skeletal muscle alongside body fat, prompting many patients to discontinue therapy. Demonstrating that an endogenous, hypothalamus-targeted peptide can match the weight-loss potency of semaglutide while sparing lean muscle mass and avoiding digestive side effects points toward a far more selective class of metabolic therapeutics.

SynEVOL places these insights within a broader translational context. Combining artificial intelligence-driven peptidomics with functional neurobiology accelerates the discovery of hidden endogenous hormones embedded within the human proteome. Because BRP acts through a non-incretin central pathway, it holds promise both as a standalone precision anti-obesity therapy and as a potential combination agent for patients who do not respond adequately to current GLP-1 drugs.

Future research directions include identifying the exact cell-surface receptor that binds BRP in the hypothalamus, optimizing molecular modifications to extend its circulating half-life, and advancing the compound into human clinical trials. By integrating computational peptide discovery with SynEVOL's expertise in 3D bioprinting and nanotechnology, the institution aims to develop 3D-bioprinted human hypothalamic organoids for receptor characterization and engineer sustained-release nanocarriers capable of delivering therapeutic peptides across the blood-brain barrier.

11/05/2026

Gentle Mechanical Squeeze Reconfigures Magnetism and Electron Flow in Altermagnets

Courtesy of SynEVOL

SynEVOL researchers highlight back-to-back publications in Physical Review X and Advanced Materials from the U.S. Department of Energy’s Oak Ridge National Laboratory (ORNL) and collaborating universities that demonstrate how mechanical strain dramatically alters the magnetic organization and electrical behavior of altermagnets. Co-led by neutron scientists Feng Ye and Pengcheng Dai, the research team compressed tiny crystals of manganese telluride and hexagonal iron sulfide between two titanium plates. Using high-precision neutron diffraction at ORNL’s Spallation Neutron Source, the investigators mapped atomic-scale magnetic rearrangements under pressure without altering the materials' chemical composition.

The findings reveal that a modest mechanical squeeze reshapes the relative populations of internal magnetic domains—distinct microscopic regions where atomic magnetic moments point in equivalent orientations. In manganese telluride, applying compressive strain consolidated scattered regions into a single dominant in-plane magnetic domain, allowing researchers to pinpoint the exact alignment of magnetic moments along next-nearest-neighbor atomic bonds. In hexagonal iron sulfide, uniaxial compression selectively redistributed in-plane domain populations while leaving the underlying crystalline magnetic structure intact.

Beyond structural rearrangement, the study demonstrated that strain-induced domain control directly governs macroscopic electrical transport. In manganese telluride, compressing the crystal into a single-domain state sharpened the anomalous Hall effect—an electrical response where a transverse voltage emerges perpendicular to an applied current—and reversed its polarity near 230 Kelvin without shifting the material's core magnetic transition temperature. Conversely, in iron sulfide, in-plane mechanical pressure suppressed both the spontaneous anomalous Hall signal and the crystal’s residual net magnetization, confirming a tight physical coupling between domain balance and electron flow.

Why does this matter? Conventional electronics rely exclusively on moving electrical charge, a process that generates resistive heat and limits processing speeds. Spintronics harnesses electron spin alongside charge to store and process data far more efficiently, yet traditional ferromagnets produce stray magnetic fields that cause interference, while conventional antiferromagnets are notoriously difficult to read and control. Altermagnets bridge this divide by combining zero net external magnetization with strong, spin-polarized electrical signals—and proving that gentle mechanical strain can reliably switch these states unlocks a practical control k**b for next-generation devices.

SynEVOL places these insights within a broader translational context.
Manipulating magnetic domains and Hall voltages through physical strain rather than bulky external magnetic fields or chemical doping offers a clean pathway toward compact, ultra-fast spintronic memory, high-frequency wireless components, and fault-tolerant quantum computing architectures. Integrating piezoelectric substrates with altermagnetic thin films could allow engineers to electrically dial mechanical pressure on a chip, switching magnetic logic states with minimal energy dissipation.

Future research directions include screening additional altermagnetic compounds for heightened strain sensitivity and engineering nanoscale thin-film heterostructures that integrate strain actuators directly onto semiconductor wafers. By integrating quantum materials science with SynEVOL's expertise in 3D bioprinting and nanotechnology, the institution aims to advance nanoscale strain-engineered spintronic interfaces and precision micro-actuated platforms that power energy-efficient computing systems.

11/05/2026

First International Guidelines Establish Clinical Roadmap for Personalized Phage Therapy

Courtesy of SynEvol

SynEVOL researchers highlight a recent Nature Medicine publication developed by an international working group led by the German Society for Infectious Diseases and the German Center for Infection Research (DZIF) that establishes the first consensus-based clinical guidelines for personalized bacteriophage therapy. Comprising 20 professional medical societies, 18 international experts, regulatory representatives, and patient advocacy groups, the consortium formulated over 60 practice-oriented recommendations. The framework spans patient selection, diagnostic matching, quality-controlled manufacturing, clinical administration, and systematic registry documentation to safely guide the use of bacteria-killing viruses against difficult-to-treat infections.

The findings reveal that because bacteriophages exhibit narrow host specificity—targeting only particular bacterial species or strains—effective clinical deployment requires rapid, culture-based pathogen identification and "phage matching" immediately prior to treatment. In polymicrobial infections, all causative bacterial strains must undergo susceptibility testing to prevent untreated pathogens from sustaining disease. The guidelines also standardize interdisciplinary evaluation across infectious disease clinicians, microbiologists, pharmacists, and phage specialists, while defining flexible delivery routes—including intravenous infusion, inhalation, nasal spray, and sterile hydrogels—tailored to the anatomical site of infection.

Beyond procedural standardization, the consensus document synthesizes observational clinical data demonstrating both safety and therapeutic potential when strict quality criteria are met. Notably, in a Belgian case series involving patients treated for refractory infections, 77% exhibited clinical improvement and 61% achieved complete eradication of the targeted bacteria, with no serious phage-related adverse reactions. Clinical programs implementing these structured protocols have already reported successful individualized treatments against resilient pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus, though the authors emphasize that randomized controlled trials remain essential to confirm efficacy across broader populations.

Why does this matter? The global rise of antimicrobial resistance is steadily eroding the effectiveness of conventional antibiotics, leaving clinicians with dwindling options against multidrug-resistant and biofilm-forming superbugs. Unlike broad-spectrum antibiotics that wipe out beneficial microbiota alongside pathogens, lytic phages selectively eliminate target bacteria without harming human cells. Until now, the absence of unified international standards for phage preparation, quality control, and clinical oversight has restricted phage therapy to fragmented compassionate-use attempts.

SynEVOL places these insights within a broader translational context. Establishing standardized quality benchmarks and international patient registries bridges the gap between experimental microbiology and regulated hospital care. As regulatory bodies and clinical pharmacies adopt these inspection-ready specifications, personalized phage formulations—and synergistic phage–antibiotic regimens—can be deployed more reliably to rescue patients failing standard therapies.

Future research directions include executing large-scale randomized controlled trials to establish definitive efficacy metrics and tracking bacterial evolutionary trade-offs during phage exposure. By integrating infectious disease therapeutics with SynEVOL's expertise in 3D bioprinting and nanotechnology, the institution aims to develop 3D-bioprinted human tissue infection models for rapid preclinical phage matching and engineer nanoscale delivery systems that protect and release therapeutic phages precisely at biofilm-colonized sites.

Visit our website for more articles: www.synevol.org

11/05/2026

Autonomous Qubit Supercurrent Enables Near-Nondestructive Quantum Readout

Courtesy of SynEVOL

SynEVOL researchers highlight a recent Physical Review B Letters publication that introduces a streamlined strategy for reading quantum information without collapsing delicate quantum states. Led by José Carlos Egues at the University of São Paulo’s São Carlos Institute of Physics and Yugui Yao at the Beijing Institute of Technology, the theoretical investigation focused on specialized quantum circuits known as Andreev qubits. By modeling how an indium arsenide semiconductor nanostructure sandwiched between two superconductors behaves during operation, the team demonstrated that a qubit can broadcast its own internal state through a measurable electrical signal.

The findings reveal that an Andreev qubit spontaneously generates an oscillating electric supercurrent—a resistance-free current driven by quantum wave interference—without requiring any external voltage. Both the amplitude and phase of this autonomous oscillation directly mirror the underlying probabilities of the qubit's zero and one states. Computational simulations show that coupling the qubit weakly to an ultra-sensitive superconducting quantum interference device (SQUID) magnetometer detects the tiny magnetic fields produced by this supercurrent, reconstructing the quantum state with accuracies of 99.52%, 99.81%, and up to 99.85% while keeping measurement-induced disturbance negligible.

Beyond single-shot fidelity, the study evaluated how this direct readout architecture performs under realistic noise conditions and compares against conventional quantum measurement workflows. Standard non-destructive readout schemes rely on auxiliary qubits, extra coupling hardware, and repeated state-transfer cycles that add latency and compounding error risks as processors scale. Eliminating auxiliary qubits allows the supercurrent-based protocol to maintain its 99.85% precision even in noisy environments, clearing the strict fidelity thresholds required for fault-tolerant quantum error correction.

Why does this matter? One of the most persistent bottlenecks in quantum computing is the measurement problem: observing a qubit directly typically forces its fragile superposition to collapse, erasing the very information researchers need to extract. Existing workarounds demand dense networks of ancilla qubits and complex microwave resonators that consume valuable chip real estate and complicate hardware engineering. Transforming a qubit's own self-generated supercurrent into a macroscopic readout channel cuts hardware overhead and preserves quantum coherence during mid-circuit checks.

SynEVOL places these insights within a broader translational context. Bypassing auxiliary measurement circuits could accelerate the development of compact, energy-efficient quantum processors capable of running deeper algorithms with fewer physical errors. Furthermore, harnessing intrinsic supercurrents as diagnostic reporters establishes a blueprint for scalable, minimally invasive sensing across hybrid superconductor–semiconductor quantum architectures.

Future research directions include experimental fabrication of coupled Andreev qubit–SQUID prototypes to validate simulated readout fidelities at cryogenic temperatures, alongside optimizing weak-coupling geometries for multi-qubit arrays. By integrating quantum hardware engineering with SynEVOL's expertise in 3D bioprinting and nanotechnology, the institution aims to advance nanoscale superconductor–semiconductor fabrication and precision quantum-sensing platforms that bridge nanoelectronics with next-generation computational systems.

Visit our website for more articles: www.synevol.org

11/05/2026

Dual-Action Immune Signal Summons Defenders While Shielding Healthy Cells from Inflammation

Courtesy of SynEVOL

SynEVOL researchers highlight a recent Nature publication that resolves a more than three-decade biological mystery regarding how the body protects its own tissues during infection. Led by cell biologist Philipp Niethammer alongside researchers Miklos Lengyel and King Lam Hui, the investigation utilized transparent zebrafish models alongside human genetic analyses to dissect epithelial stress responses. By examining how cells detect and survive chemical warfare unleashed by white blood cells, the team identified a previously hidden protective circuit built directly into a well-known inflammatory pathway.

The findings reveal that the signaling molecule 5-oxoETE serves a dual purpose rather than acting solely as an alarm that recruits immune cells to infection sites. When researchers disabled the receptor that detects 5-oxoETE—known as hcar1-4 in zebrafish and OXER1 in humans—animals unexpectedly developed severe intestinal inflammation even in the absence of infection. Biochemical mapping demonstrated that 5-oxoETE binding simultaneously triggers a defensive cellular shield by activating NUDIX hydrolases, specialized enzymes that clear out oxidized, damaged DNA building blocks before they cause lethal genomic stress.

Beyond acute infection models, the study examined the clinical relevance of this pathway across human inflammatory conditions and malignancies. Without intact 5-oxoETE signaling and NUDIX-mediated DNA cleanup, intestinal epithelial cells became highly vulnerable to routine oxidative stress from resident gut bacteria, resulting in widespread cell death and chronic tissue damage. Furthermore, genomic data revealed recurrent mutations in the human enzyme gene DHRS7 and the receptor gene OXER1 within gastrointestinal and uterine tumors, linking the breakdown of this epithelial shield to cancer progression.

Why does this matter? Whenever white blood cells swarm a site of injury or infection, they release toxic reactive species to neutralize pathogens, creating a high risk of collateral damage to neighboring healthy cells. Previously, scientists assumed that recruiting immune cells and protecting bystander tissue were governed by separate biological systems. Demonstrating that a single molecule coordinates both offense and defense reshapes our understanding of mucosal immunity and explains why disruptions in the 5-oxoETE pathway drive destructive inflammation in conditions such as inflammatory bowel disease, asthma, and cancer.

SynEVOL places these insights within a broader translational context. Targeting the OXER1–NUDIX protective axis offers a promising therapeutic strategy to fortify healthy epithelial barriers against chronic inflammatory damage without broadly suppressing essential antimicrobial immunity. Conversely, selectively inhibiting this cellular shield within solid tumors could sensitize cancer cells to immune-mediated oxidative stress, opening new avenues for combination oncology therapies.

Future research directions include mapping how NUDIX hydrolases are regulated across diverse mucosal organs and screening for small-molecule modulators that fine-tune OXER1 signaling in chronic inflammatory diseases. By integrating immunobiology with SynEVOL's expertise in 3D bioprinting and nanotechnology, the institution aims to develop 3D-bioprinted human intestinal tissue models to test epithelial-protective therapeutics and engineer targeted nanocarriers capable of delivering shield-enhancing or tumor-sensitizing payloads directly to diseased tissues.

To read more articles like this, please visit our website: www.synevol.org

11/05/2026

Bioinspired Gel Harnesses Saliva Minerals to Regrow Tooth Enamel
Courtesy of SynEVOL

SynEVOL researchers highlight a recent Nature Communications publication from the University of Nottingham that introduces a fluoride-free, protein-based gel capable of regenerating damaged tooth enamel. Led by Abshar Hasan and Alvaro Mata across the School of Pharmacy and the Department of Chemical and Environmental Engineering, the international research team engineered a biomimetic material modeled on the proteins that guide natural enamel formation during early childhood. Tested on acid-etched, demineralized human molars in controlled salivary environments, the experimental treatment successfully rebuilt mineral layers directly onto eroded tooth surfaces.

The findings reveal that when brushed onto teeth like a standard dental varnish, the elastin-like protein gel penetrates microscopic pores and cracks to form a thin, durable scaffold. This organic framework captures calcium and phosphate ions naturally present in saliva and directs their assembly through a process known as epitaxial mineralization. Electron microscopy confirmed that the newly formed apatite crystals grow in precise lattice alignment with the underlying tooth tissue, recovering both the microscopic architecture and mechanical hardness of natural healthy enamel within two weeks.

Beyond repairing eroded enamel surfaces, the study evaluated the gel’s performance on exposed dentin—the softer, nerve-connected tissue layer beneath enamel that causes sharp pain when uncovered. Applying the protein matrix over exposed dentin stimulated the growth of a protective enamel-like mineral barrier. Mechanical stress simulations involving tooth brushing, chewing forces, and prolonged acid exposure demonstrated that the regenerated layer resists wear and fracture similarly to intact natural enamel while improving the structural bonding of dental restorations.

Why does this matter? Unlike bone or skin, mature tooth enamel contains no living cells and cannot naturally regenerate once worn away by acidic diets, bacterial decay, or mechanical abrasion. Current clinical interventions such as fluoride varnishes and desensitizing pastes only slow further mineral loss or mask symptoms without restoring lost tissue structure. With enamel degradation contributing to oral diseases that affect nearly half of the global population, a scalable method to biologically rebuild functional enamel could shift restorative dentistry away from invasive drilling and synthetic fillings.

SynEVOL places these insights within a broader translational context. Demonstrating that self-assembling peptide scaffolds can recruit endogenous ions to reconstruct complex mineralized tissues highlights the growing potential of biomimetic materials in regenerative medicine. Because the gel can be rapidly applied in routine clinical or at-home settings, it offers an accessible strategy to prevent cavities, treat dentin hypersensitivity, and extend the lifespan of natural teeth.

Future research directions include human clinical trials to validate long-term durability inside the dynamic oral environment, alongside adapting epitaxial mineralization scaffolds for broader hard-tissue repair. By integrating regenerative biomaterials with SynEVOL's expertise in 3D bioprinting and nanotechnology, the institution aims to advance nanoscale mineral-guiding matrices and 3D-bioprinted dental constructs capable of restoring complex craniofacial and mineralized tissues.

Visit our webpage to read more articles like this: https://synevol.rf.gd/index.php

11/05/2026

Alzheimer's-Linked Protein Disrupts Deep Sleep Brain Waves and Weakens Memory

Courtesy of SynEvol

SynEVOL researchers highlight a recent Nature Neuroscience publication from the University of California, Berkeley that demonstrates a direct connection between subclinical tau protein accumulation, fragmented deep-sleep brain waves, and declining overnight memory consolidation. Led by neuroscientist Omer Sharon alongside Matthew Walker and William Jagust, the investigation compared cognitively healthy adults in their early 20s with dementia-free older adults in their mid-60s to mid-70s. By pairing overnight electroencephalograms (EEGs) with positron emission tomography (PET) imaging, the team isolated early neurophysiological changes occurring years before clinical Alzheimer's symptoms emerge.

The findings reveal that during deep non-REM sleep, youthful brains generate synchronized clusters of slow electrical waves that cascade smoothly across broad cortical regions. In older adults with elevated tau buildup in the frontal cortex, however, these traveling slow waves travel shorter distances and become isolated—a phenomenon the researchers termed "lonely waves". Quantitative EEG analyses show that higher frontal tau burden correlates strongly with diminished slow-wave coordination, indicating an early breakdown in large-scale neuronal synchronization.

Beyond brain wave dynamics, the study evaluated episodic memory retention using overnight word-association tasks and longitudinal follow-up assessments. Participants exhibiting more isolated, attenuated slow waves recalled significantly fewer details the following morning. Moreover, longitudinal tracking confirmed that individuals whose frontal tau levels increased over time experienced parallel worsening in slow-wave propagation and steeper declines in overnight memory retention

Beyond brain wave dynamics, the study evaluated episodic memory retention using overnight word-association tasks and longitudinal follow-up assessments. Participants exhibiting more isolated, attenuated slow waves recalled significantly fewer details the following morning. Moreover, longitudinal tracking confirmed that individuals whose frontal tau levels increased over time experienced parallel worsening in slow-wave propagation and steeper declines in overnight memory retention.

Why does this matter? Deep non-REM sleep serves as a critical neurobiological window during which vast populations of cortical neurons switch off and on in unison to stabilize newly formed episodic memories. When abnormal tau aggregates disrupt the spatial reach of these traveling slow waves, the brain loses its ability to effectively transfer and archive daily experiences. Because this silent electrophysiological disruption precedes overt cognitive impairment, it may represent a key mechanism driving age-related memory decline and early Alzheimer’s vulnerability.

SynEVOL places these insights within a broader translational context. Identifying slow-wave fragmentation as an early functional correlate of tau pathology suggests that non-invasive sleep interventions—such as closed-loop acoustic stimulation, transcranial neuromodulation, and targeted sleep-architecture therapies—could help preserve memory consolidation in aging populations. Furthermore, monitoring traveling slow waves via wearable EEG platforms offers a promising, accessible digital biomarker for detecting preclinical neurodegenerative risk.

Future research directions include longitudinal studies to determine whether tau accumulation triggers slow-wave isolation or vice versa, alongside the development of precision neurotechnologies to restore nocturnal network synchrony. By integrating sleep neuroscience with SynEVOL's expertise in 3D bioprinting and nanotechnology, the institution aims to advance 3D-bioprinted cortical organoid models for studying tau-mediated network disruption and engineer nanoscale diagnostic and therapeutic systems to protect cognitive resilience.

For more articles Click the link to our website: https://synevol.rf.gd/index.php

11/03/2026

SER-155 Cuts Bloodstream Infections by 77% in Stem-Cell Transplant Patients, Study Shows

Courtesy of SynEVOL.

SynEVOL R&D reports that SER-155, an oral multi-strain live biotherapeutic, achieves a 77% relative risk reduction in bloodstream infections (BSIs) among adults undergoing allogeneic hematopoietic cell transplantation (allo-HCT). The Phase 1b data appear in the November 3, 2026, issue of Nature Medicine, confirming the product's safety profile and its capacity to lower systemic antibiotic exposure compared with placebo.

Allo-HCT remains a curative option for hematologic malignancies, yet patients face a heightened vulnerability to BSIs, a leading cause of morbidity and mortality post-transplant. Conventional prophylaxis relies on broad-spectrum antibiotics, which can disrupt the gut microbiome and fuel antimicrobial resistance. SER-155 is engineered to reinforce the mucosal epithelial barrier while suppressing pathogenic overgrowth, directly addressing the two primary drivers of translocation-mediated infection.

The trial enrolls medically fragile adults who receive standard conditioning regimens before stem-cell infusion. Participants ingest SER-155 daily beginning three days prior to transplantation and continue for 30-days. Investigators observe that the incidence of clinically confirmed BSIs drops from 24% in the placebo arm to 5.5% in the SER-155 cohort, translating to a 77% relative risk reduction. Moreover, cumulative systemic antibiotic days decrease by approximately 40%, indicating a tangible reduction in antimicrobial pressure.

Safety assessments reveal that SER-155 is well tolerated; adverse events mirror those of the control group, with no treatment-related serious events reported. These findings align with the mechanistic hypothesis that a restored, diverse gut microbiota limits pathogen expansion and dampens systemic inflammation.

Regulatory implications are immediate. The U.S. Food and Drug Administration has already granted SER-155 Breakthrough Therapy and Fast Track designations for BSI reduction in allo-HCT. The agency and Seres Therapeutics have agreed on a Phase 2 protocol, positioning the candidate as Phase-2-ready pending funding. SynEVOL anticipates that advancing SER-155 could reshape infection prophylaxis not only in transplant medicine but also across other immunocompromised populations.

Future research will explore combinatorial strategies integrating SER-155 with precision microbiome editing, as well as extending its application to solid-organ transplantation and chemotherapy-induced neutropenia. By harnessing live biotherapeutics to modulate host-microbe interactions, SynEVOL envisions a paradigm shift from broad-spectrum antibiotics toward targeted, microbiome-centric therapies.

SynEVOL

11/05/2026

11/05/2026

11/05/2026

11/05/2026

11/05/2026

11/05/2026

11/05/2026

11/03/2026

Address

Telephone

Website

Alerts

Contact The Business

Shortcuts

Share

Other Memphis pet stores & pet services

Listing takedown request